



July 1, 2019

To: All Concerned Parties

Company Name: Solasia Pharma K.K.
Representative: Yoshihiro Arai, President & CEO
(Code number: 4597, TSE Mothers Section)
Contact: Toshio Miyashita, CFO, Director
Tel: 81-3-5843-8049

Solasia Makes First Shipment of episil® (SP-03) to China

Solasia Pharma K.K. (hereinafter “Solasia”), a specialty pharmaceutical company based in Asia, officially announced today that Solasia has made its first shipment of episil® oral liquid (SP-03, hereinafter “episil®”) for Chinese market to Itochu Corporation which is the counterpart of the sales distribution agreement for episil® in China market on June 28, 2019.

episil® has a physical mechanism indicated for the management and relief of pain, soothing oral lesions by adhering to the mucosal surface of the oral cavity. It can be used for oral mucositis/stomatitis caused by chemotherapy and/or radiotherapy, and was approved by the Chinese authority in February 2019.

Following this shipment, episil® will be launched in China during FY2019. Same as Sancuso® (SP-01), Solasia will commercialize using its own sales force in Beijing, Shanghai, and Guangzhou. As for the rest of China, it will be commercialized by Lee’s Pharmaceutical (HK) Limited.

With this shipment, Solasia will record revenue. The impact of this event has been already included in the current fiscal year’s financial forecast, thus no change in financial forecast will be announced as of now.

Disclaimer:

The forward-looking statements, including earnings forecasts, contained in this press release are based on information currently available to the Company and on certain assumptions deemed to be reasonable. Such statements should not be construed as representing commitments on the part of the Company. Please be aware that actual performance may differ for a variety of reasons. Major factors affecting the Company’s actual performance include the economic conditions in which it operates, exchange rate fluctuations, the competitive situation and other factors. Information contained in this press release with regard to pharmaceuticals and medical devices (including products under development) is not provided for the purposes of advertising or medical advice.